prof. dr. E.G.E. (Elisabeth) de Vries


No picture available


  1. 2017
  2. Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., ... RECIST Working Grp (2017). iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncology, 18(3), E143-E152.
  3. Koch, M., de Jong, J. S., Glatz, J., Symvoulidis, P., Lamberts, L. E., Adams, A. L. L., ... Ntziachristos, V. (2017). Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer. Cancer Research, 77(3), 623-631.
  4. Oosting, S. F., de Vries, E. G. E., & Witjes, M. (2017). Molecular Imaging in Head and Neck Squamous Cell Carcinoma Patients. In J. B. Vermorken, V. Budach, C. R. Leemans, J-P. Machiels, P. Nicolai, & B. O'Sullivan (Eds.), Critical Issues in Head and Neck Oncology: Key concepts from the Fifth THNO Meeting (pp. 77-96). Springer.
  5. 2016
  6. Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., ... de Vries, E. G. E. (2016). ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers. ESMO Open, 1(5), [000100].
  7. Schwartz, L. H., Litiere, S., Vries, de, E. G. E., Ford, R., Gwyther, S., Mandrekar, S., ... Seymour, L. (2016). RECIST 1.1-Update and clarification: From the RECIST committee. European Journal of Cancer, 62, 132-137.
  8. 2015
Previous 1 2 3 4 5 6 7 8 ...20 Next

ID: 162081